Merck & Co Takes A Punt On Evaxion’s AI Vaccines
Executive Summary
Deal Snapshot: Merck likes the look of Evaxion's artificial intelligence-based technology platform to develop immunotherapies and signed a biobucks deal that will help ease the Copenhagen-headquartered biotech's financial situation.